Condition: Attention-Deficit/Hyperactivity Disorder · Sponsor: Supernus Pharmaceuticals, Inc.
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
This description comes directly from the study's public registry record.
Joseph T Hull, PhD · 240-403-5324 · jhull@supernus.com
Leslie Brijbasi · 301-838-2519 · lbrijbasi@supernus.com
Always discuss trial participation with your own doctor first.
| The Center for Clinical Trials, Inc. | Saraland, Alabama, United States | Recruiting |
| Preferred Research Partners, Inc. | Little Rock, Arkansas, United States | Recruiting |
| Advanced Research Center (ARC), Inc. | Anaheim, California, United States | Recruiting |
| Sun Valley Research Center | Imperial, California, United States | Recruiting |
| Alliance Research | Long Beach, California, United States | Recruiting |
| IMMUNOe Research Centers | Centennial, Colorado, United States | Recruiting |
| Luna Research Center | Coral Gables, Florida, United States | Recruiting |
| Sarkis Clinical Trials | Gainesville, Florida, United States | Recruiting |
| Clinical Neuroscience Solutions, Inc. | Jacksonville, Florida, United States | Recruiting |
| Avantis Clinical Research LLC | Miami, Florida, United States | Recruiting |
| Hope Research Network, LLC. | Miami, Florida, United States | Recruiting |
| Medical Research Group of Central Florida | Orange City, Florida, United States | Recruiting |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04781140